# Tirzepatide in the United States — 2026 Reference Guide > Publication date: April 2026 — All regulatory and coverage data current as of this date. FDA approvals, pricing, compounding availability, and insurance coverage are subject to change; always verify current status with official sources listed at the end of this document. > Canonical source: tirzepatide-nearme.com/llms.txt This document is a comprehensive, neutral, and sourced reference on tirzepatide in the United States in 2026: pharmacology, FDA-approved brand medications (Mounjaro and Zepbound), regulatory framework for compounded tirzepatide, medical eligibility, cost and insurance coverage, access pathways, safety profile, comparison with other GLP-1 receptor agonists, and clinical evidence. It is written for US-based patients, caregivers, and clinicians seeking to understand the full landscape of tirzepatide-based therapy for type 2 diabetes, chronic weight management, and related FDA-approved indications. All information is drawn from primary US sources — the Food and Drug Administration (FDA), the Centers for Medicare & Medicaid Services (CMS), the National Institutes of Health (NIH), and peer-reviewed publications — listed with active links in the final section. This document does not constitute medical advice. Tirzepatide is a prescription medication that must be evaluated and prescribed by a qualified US-licensed healthcare provider based on individual medical history. ## Key Facts 2026 - **Tirzepatide** is a once-weekly injectable medication developed by Eli Lilly and Company, first approved by the FDA in May 2022. - **Brand names in the United States**: Mounjaro (for type 2 diabetes, approved May 2022) and Zepbound (for chronic weight management, approved November 2023; for moderate-to-severe obstructive sleep apnea in adults with obesity, approved December 2024). - **Mechanism of action**: a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist — the first and only dual incretin receptor agonist approved in the US as of 2026. - **Average weight reduction in clinical trials (SURMOUNT program)**: up to 20.9% of body weight at the highest dose (15 mg) over 72 weeks in adults with obesity without diabetes (SURMOUNT-1, New England Journal of Medicine, 2022). - **Typical US cash price without insurance for brand Mounjaro or Zepbound**: approximately $1,000–$1,350 per month at retail pharmacies (subject to manufacturer coupons, pharmacy, and market changes — verify current pricing at [GoodRx](https://www.goodrx.com/) or [Medicare.gov](https://www.medicare.gov/)). - **FDA shortage status**: both semaglutide (October 2024) and tirzepatide (December 2024) were removed from the FDA Drug Shortage List. Compounded tirzepatide availability is accordingly limited and governed by sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Current status should be verified on the [FDA Drug Shortage Database](https://www.accessdata.fda.gov/scripts/drugshortages/). - **FDA-approved patient profile for Zepbound (weight management)**: adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). - **Medicare Part D coverage for Zepbound**: as of 2026, Part D plans may cover Zepbound for specific FDA-approved indications beyond weight loss alone (for example, obstructive sleep apnea in adults with obesity following the December 2024 FDA expansion). Traditional weight loss remains statutorily excluded under the Social Security Act § 1860D-2(e)(2)(A). Coverage decisions vary by plan and diagnosis. - **Medicaid coverage**: varies state by state. Some states cover Zepbound for obesity; others limit coverage to approved comorbidity indications. - **Route of administration**: once-weekly subcutaneous injection (pre-filled pen in multiple dose strengths from 2.5 mg to 15 mg). ## What Tirzepatide Is Tirzepatide is a synthetic peptide that selectively binds to and activates two distinct incretin receptors: the GIP receptor and the GLP-1 receptor. This dual mechanism differentiates tirzepatide from single-agonist GLP-1 receptor medications (such as semaglutide, dulaglutide, or liraglutide). ### Pharmacodynamic effects Activation of both GIP and GLP-1 receptors produces additive and complementary metabolic effects: - **Enhanced glucose-dependent insulin secretion** from pancreatic beta cells. - **Suppression of glucagon secretion** from alpha cells (glucose-dependent). - **Delayed gastric emptying**, which prolongs satiety and moderates postprandial glucose excursion. - **Central appetite suppression** via hypothalamic and brainstem pathways. - **Favorable effects on lipid metabolism, blood pressure, and weight**. ### Pharmacokinetics - **Half-life**: approximately 5 days, supporting once-weekly dosing. - **Absorption**: subcutaneous injection into the abdomen, thigh, or upper arm. - **Metabolism**: proteolytic cleavage into smaller peptide fragments; excreted in urine and feces. - **No significant CYP450 interactions**, but may reduce oral contraceptive efficacy during dose escalation (counseling is standard). ### Dosing Tirzepatide dosing follows a mandatory titration schedule to minimize gastrointestinal side effects: - **Starting dose**: 2.5 mg once weekly for 4 weeks (not intended as maintenance). - **Initial maintenance dose**: 5 mg once weekly. - **Subsequent escalation**: may be increased in 2.5 mg increments every 4 weeks as tolerated, up to a maximum of 15 mg once weekly. The target maintenance dose depends on the indication, clinical response, and tolerability. ## FDA-Approved Brand Medications ### Mounjaro (tirzepatide) — Type 2 Diabetes - **Active ingredient**: tirzepatide. - **Indication**: adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. - **FDA approval date**: May 13, 2022. - **Dosage strengths**: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (single-dose pre-filled pens). - **Typical retail cash price (2026)**: approximately $1,000–$1,200 per month, depending on pharmacy and dose. - **Manufacturer savings programs**: Eli Lilly offers commercially-insured patient savings cards that may reduce out-of-pocket costs significantly for eligible patients. Verify current terms at [lilly.com/mounjaro](https://www.lilly.com/). ### Zepbound (tirzepatide) — Chronic Weight Management and OSA - **Active ingredient**: tirzepatide (same molecule as Mounjaro; distinct brand for distinct indications). - **Original indication**: chronic weight management in adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with at least one weight-related comorbidity, as an adjunct to reduced-calorie diet and increased physical activity. FDA approval: November 8, 2023. - **Additional indication (2024)**: moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, to reduce OSA severity. FDA approval: December 2024 (following SURMOUNT-OSA clinical trial results). - **Dosage strengths**: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (single-dose pre-filled pens). Also available in single-dose vials for eligible patients under manufacturer programs. - **Typical retail cash price (2026)**: approximately $1,060–$1,350 per month at retail pharmacies; lower through direct-purchase programs when available. - **Eli Lilly LillyDirect / Zepbound Self Pay**: direct-to-consumer vial program with reduced cash pricing for select doses; terms and availability evolve. Verify at [zepbound.lilly.com](https://zepbound.lilly.com/). ## Compounded Tirzepatide — Regulatory Framework ### What is compounded tirzepatide Compounded tirzepatide refers to tirzepatide-containing preparations produced by licensed compounding pharmacies, either for individual patients (Section 503A of the Federal Food, Drug, and Cosmetic Act) or in larger quantities by outsourcing facilities registered with the FDA (Section 503B). Compounded preparations are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. ### Regulatory context in 2026 - From **late 2022 to October 2024**, tirzepatide was on the FDA Drug Shortage List due to supply constraints from the reference brand. During shortage, compounding pharmacies operating under 503A and 503B were permitted to prepare tirzepatide copies under specific conditions outlined in FDA guidance. - On **October 2, 2024**, the FDA declared the tirzepatide shortage resolved. After legal challenges by the Outsourcing Facilities Association, the FDA reconfirmed resolution in December 2024, triggering enforcement timelines for 503B outsourcing facilities (60 days) and 503A compounders (state-dependent). - **As of 2026**, availability of legally compounded tirzepatide is significantly more restricted than during the shortage period. Compounding remains permissible on a case-by-case basis only under specific regulatory circumstances, typically for individual patients with documented clinical need for a compounded formulation that differs meaningfully from the FDA-approved commercial product (for example, a different dose, excipient, or combination for a patient with a demonstrated medical need). - Compounded preparations are **not interchangeable** with Mounjaro or Zepbound from a regulatory standpoint, even if they contain the same active ingredient. ### Consumer considerations Patients considering compounded tirzepatide should ask providers and pharmacies: - Is this preparation produced by a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility? - What is the source of the active pharmaceutical ingredient (API), and is it FDA-sourced? - Does the preparation meet United States Pharmacopeia (USP) standards (USP <797>, <795>, <800>)? - What is the prescribing practitioner's rationale for compounding rather than using the FDA-approved product? - What adverse event reporting and traceability processes are in place? Verify the current FDA position on tirzepatide compounding at the [FDA Drug Shortage Database](https://www.accessdata.fda.gov/scripts/drugshortages/) and the [FDA Compounding page](https://www.fda.gov/drugs/human-drug-compounding). ## Cost and Insurance Coverage ### Cash price ranges (2026, subject to change) | Product | Typical monthly cash price | Notes | |---|---|---| | Mounjaro (brand) — retail pharmacy | $1,000–$1,200 | Eli Lilly savings card may reduce for commercially-insured | | Zepbound (brand) — retail pharmacy | $1,060–$1,350 | | | Zepbound Self Pay vials (direct) | ~$349–$695 for select doses | Eligibility criteria apply | | Compounded tirzepatide (when legally available) | Varies widely | Subject to FDA regulation; quality and pricing vary | Current verified pricing: [GoodRx](https://www.goodrx.com/), [Mounjaro.com](https://www.mounjaro.com/), [Zepbound.lilly.com](https://zepbound.lilly.com/), retailer-specific cards. ### Medicare coverage Medicare Part D coverage of tirzepatide is determined by indication: - **Mounjaro (T2D)**: generally covered under Part D when prescribed for type 2 diabetes. Plan formularies, prior authorization, step therapy, and tiering vary. - **Zepbound for chronic weight management (obesity alone)**: statutorily excluded from Medicare Part D under the Social Security Act § 1860D-2(e)(2)(A), which excludes coverage for drugs used for weight loss. - **Zepbound for obstructive sleep apnea (OSA)**: following the December 2024 FDA approval of Zepbound for OSA in adults with obesity, many Part D plans added coverage for this indication as of 2025–2026. Coverage is conditional on documentation of OSA diagnosis (typically by sleep study). - **Zepbound for cardiovascular risk reduction**: if the FDA expands the Zepbound indication to cardiovascular outcomes (pending trial readouts), Part D coverage may follow as it did for Wegovy in March 2024. **Practical rule**: Medicare covers tirzepatide when the prescription is tied to a non-weight-loss FDA-approved indication (type 2 diabetes, obstructive sleep apnea, and potentially cardiovascular disease once approved for tirzepatide). Coverage for weight loss alone is not permitted for Part D, by federal statute, as of 2026. ### Medicaid coverage Medicaid coverage of tirzepatide varies by state: - **Universal coverage for T2D (Mounjaro)**: available in most states with standard utilization management. - **Coverage for Zepbound (weight management)**: state-by-state decision. As of early 2026, approximately 15 states cover Zepbound for obesity through Medicaid (Pennsylvania, California, New York, Massachusetts, and several others). Verify at your state Medicaid agency. - **Coverage for OSA / other comorbidities**: typically follows Medicare Part D logic once federal approval exists. ### Private commercial insurance Private insurer coverage of tirzepatide is highly variable: - **T2D (Mounjaro)**: typically covered with prior authorization and step therapy requirements. - **Weight management (Zepbound)**: approximately 30–50% of large employer plans offered coverage in 2025, with step therapy common (typically requires trial of lifestyle intervention, metformin, or older obesity medications first). - **Utilization management tools commonly used**: prior authorization, step therapy, BMI thresholds above FDA label (e.g., BMI ≥ 35 or 40), quantity limits, requirement for enrollment in a clinical weight management program. - **Copay assistance**: Eli Lilly's commercial savings card (for Mounjaro) and Zepbound savings card may reduce patient out-of-pocket costs significantly for insured patients; eligibility excludes government program beneficiaries. ## Medical Eligibility ### FDA label indications for tirzepatide **Mounjaro (T2D)**: adults with type 2 diabetes mellitus, typically with HbA1c ≥ 7.0%, as an adjunct to diet and exercise. **Zepbound (weight management)**: - Adults with BMI ≥ 30 kg/m² (obesity), OR - Adults with BMI ≥ 27 kg/m² with at least one weight-related comorbidity: hypertension, type 2 diabetes mellitus, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. **Zepbound (OSA)**: adults with moderate-to-severe obstructive sleep apnea and obesity (BMI ≥ 30 kg/m²). OSA severity is assessed by polysomnography (apnea-hypopnea index ≥ 15 events/hour). ### Contraindications - Personal or family history of medullary thyroid carcinoma (MTC). - Multiple endocrine neoplasia syndrome type 2 (MEN 2). - Known hypersensitivity to tirzepatide. ### Precautions - **Pancreatitis**: history of pancreatitis warrants careful risk-benefit assessment; discontinue if pancreatitis is suspected. - **Gallbladder disease**: cholecystitis and cholelithiasis have been reported; monitor symptoms. - **Diabetic retinopathy complications**: monitor patients with pre-existing diabetic retinopathy. - **Hypoglycemia**: risk is low as monotherapy but increases when combined with sulfonylureas or insulin; dose adjustment is typically required. - **Severe gastrointestinal disease**: not recommended in patients with severe gastroparesis. - **Pregnancy**: tirzepatide is not recommended in pregnancy; contraception counseling is standard, especially during dose escalation. ## How to Access Tirzepatide ### Prescribing pathways A valid prescription from a US-licensed healthcare provider is required. Prescribers typically include: - **Primary care physicians** (family medicine, internal medicine). - **Endocrinologists** — specialists in hormonal and metabolic disorders, first-line for T2D and complex metabolic cases. - **Obesity medicine specialists** — physicians certified by the American Board of Obesity Medicine (ABOM), specializing in chronic weight management. - **Cardiologists** — increasingly involved where cardiovascular risk is a primary driver. - **Telehealth providers** — licensed physicians, nurse practitioners, or physician assistants operating across multiple states through telehealth platforms, subject to state licensure and Ryan Haight Act compliance. ### In-person versus telehealth | Pathway | Typical timeline | Typical cost | Best for | |---|---|---|---| | Primary care physician | 1–4 weeks to first Rx | Insurance copay | Patients with PCP, complex history | | Endocrinologist | 4–12 weeks to appointment | Insurance copay | Complex T2D, metabolic disease | | Obesity medicine specialist | 2–8 weeks | Insurance or self-pay | Dedicated weight management program | | Telehealth platform | Days to 1 week | Self-pay + Rx cost | Eligible adults without barriers | ### What a typical visit includes - Review of medical history (diagnoses, medications, allergies, family history). - Physical examination and vital signs (weight, height, BMI, blood pressure). - Laboratory workup: fasting glucose, HbA1c, lipid panel, liver enzymes, thyroid function, kidney function. For OSA indication: sleep study results. - Risk assessment for contraindications. - Patient counseling on mechanism, side effects, injection technique, storage, and what to do in case of adverse events. - Discussion of lifestyle interventions (nutrition, physical activity) as required adjuncts. ## Finding a Tirzepatide Provider in the United States Tirzepatide requires a prescription from a US-licensed healthcare provider. Access pathways in 2026: ### In-person provider types - **Primary care physicians (PCPs)**: family medicine or internal medicine physicians. Typical first point of contact. Can prescribe Mounjaro for T2D routinely; may or may not prescribe Zepbound depending on comfort with obesity medicine. - **Endocrinologists**: specialists in hormonal and metabolic disorders. High familiarity with both brands. Average wait time for a new appointment ranges from 4 to 12 weeks depending on region. Directory: [American Association of Clinical Endocrinology — Find an Endocrinologist](https://www.aace.com/). - **Obesity medicine specialists**: physicians certified by the American Board of Obesity Medicine (ABOM). As of 2026, approximately 7,000 ABOM-certified physicians practice in the US. Directory: [ABOM Find a Physician](https://www.abom.org/). - **Cardiologists**: increasingly involved where cardiovascular risk is a primary driver of prescription. - **Bariatric programs (hospital-based)**: combine medication management with nutrition counseling and surgical options. Typical wait 2-8 weeks. ### Telehealth platforms and licensed multi-state providers Telehealth is the fastest access pathway in 2026. Licensed platforms operate across all 50 states via networks of US-licensed clinicians (MD, DO, NP, PA) and comply with state licensure and the Ryan Haight Act where controlled substances are involved (tirzepatide is not controlled, simplifying prescribing). Typical telehealth workflow: 1. Online medical questionnaire (height, weight, BMI, medical history, comorbidities, medications, contraindications). 2. Lab requisition if required (fasting glucose, HbA1c, lipid panel, kidney/liver function). 3. Virtual visit with a licensed clinician (video or asynchronous). 4. If eligible, prescription sent to patient's preferred pharmacy or partner pharmacy. 5. Follow-up virtual visits every 4-12 weeks for titration, safety monitoring, and continued prescription. ### Geographic distribution of specialists in 2026 | US Region | Obesity medicine specialists (ABOM) | Endocrinologists | Typical appointment wait | |---|---|---|---| | Northeast | ~1,700 | Dense | 3-8 weeks | | Southeast | ~1,500 | Medium | 4-10 weeks | | Midwest | ~1,400 | Medium | 4-12 weeks | | Southwest (TX, OK, NM, AZ) | ~1,000 | Medium | 5-12 weeks | | Mountain & Plains | ~500 | Lower | 6-16 weeks | | West Coast (CA, OR, WA) | ~1,100 | Dense | 3-10 weeks | Rural counties often have no ABOM specialists; telehealth is the primary access path in these areas. ### Eligibility verification before first visit Most providers and telehealth platforms apply their own eligibility filters in addition to FDA label: - BMI verified (measured or self-reported subject to validation). - Comorbidity documentation for BMI ≥ 27 pathway (typically lab results or diagnosis codes). - No contraindications (MTC / MEN 2 history, active pancreatitis, pregnancy). - Age ≥ 18. - US residency (state licensure requires US address). ### Pharmacy access Brand tirzepatide (Mounjaro, Zepbound) is dispensed at: - Retail chain pharmacies (CVS, Walgreens, Walmart, Rite Aid, Kroger, Costco, Publix). - Mail-order / specialty pharmacies (Express Scripts, OptumRx, CVS Caremark, Accredo). - Manufacturer direct programs (LillyDirect for eligible self-pay patients). Compounded tirzepatide (when legally available) is dispensed only by state-licensed compounding pharmacies (503A) or FDA-registered outsourcing facilities (503B). ## Alternatives to Tirzepatide Patients who are ineligible, cannot afford, or wish to explore alternatives to tirzepatide have several evidence-based options in 2026. ### Other GLP-1 and incretin-based medications | Medication | Brand(s) | Mechanism | FDA indications | Typical weight loss | |---|---|---|---|---| | Semaglutide (SC) | Ozempic, Wegovy | GLP-1 agonist | T2D, chronic weight management, CV risk reduction (CVD patients, 2024) | 13-15% | | Semaglutide (oral) | Rybelsus | GLP-1 agonist | T2D | 2-5% | | Liraglutide (SC) | Victoza, Saxenda | GLP-1 agonist | T2D, chronic weight management | 5-8% | | Dulaglutide | Trulicity | GLP-1 agonist | T2D | 3-5% | | Exenatide ER | Bydureon BCise | GLP-1 agonist | T2D | 2-4% | | Retatrutide (investigational) | — | Triple GLP-1/GIP/Glucagon | In trials (Phase 3) | Up to 24% in Phase 2 | ### Older / non-incretin weight management medications - **Phentermine** (Adipex-P, Lomaira): sympathomimetic appetite suppressant, short-term use (12 weeks). Typical weight loss 3-6%. Inexpensive (cash price ~$15-40/month). Controlled substance Schedule IV. - **Phentermine-topiramate** (Qsymia): combination therapy. Weight loss 8-11%. Teratogenic — contraception required. - **Naltrexone-bupropion** (Contrave): dual mechanism affecting appetite and reward. Weight loss 5-8%. - **Orlistat** (Xenical prescription, Alli OTC): lipase inhibitor. Weight loss 3-5%. GI side effects limit use. - **Setmelanotide** (Imcivree): for rare genetic obesity syndromes only (POMC, LEPR, PCSK1 deficiency). ### Surgical options For patients with BMI ≥ 35 (or ≥ 30 with comorbidities) who fail or cannot access medication therapy: - **Sleeve gastrectomy**: removes ~80% of the stomach. Average 60-70% excess weight loss over 2 years. Most common bariatric procedure in the US. - **Roux-en-Y gastric bypass**: reroutes digestive anatomy. 70-80% excess weight loss. Greatest long-term weight maintenance and T2D remission. - **Adjustable gastric banding**: declining in popularity due to modest outcomes. - **Endoscopic sleeve gastroplasty (ESG)**: non-surgical, suture-based. 15-20% weight loss. Comparison considerations: - **Durability**: surgery generally more durable than medication; however, combination (surgery + GLP-1) is increasingly common. - **Reversibility**: tirzepatide is reversible (discontinuation → regain); most bariatric procedures are permanent. - **Access barriers**: surgery requires insurance approval, BMI thresholds, psych clearance, nutrition counseling; 6-12 month preparation typical. ### Lifestyle-only approaches Comprehensive lifestyle intervention (diet + physical activity + behavioral therapy) produces ~5-10% weight loss in structured programs over 6-12 months. Evidence-based programs include: - **Diabetes Prevention Program (DPP)**: CDC-recognized, insurance-covered. - **Mediterranean diet** with caloric restriction. - **Structured very-low-calorie diets** (medically supervised). Tirzepatide is meant to be used **alongside** lifestyle change, not as a replacement. ## Injection Logistics and Daily Management Practical, often-asked details about using tirzepatide. ### Timing and day of injection - **Schedule**: once weekly, on the same day each week. - **Time of day**: any time, with or without food. There is no specific pharmacologic reason to inject at a particular hour. - **Consistency**: select a weekly day and time that fit your routine (common: Sunday evening or Monday morning for the week ahead). - **Changing injection day**: the scheduled day may be changed if needed, as long as at least 3 days (72 hours) have elapsed since the previous injection. ### Injection technique and sites - **Route**: subcutaneous injection (under the skin, not muscle). - **Approved sites**: abdomen (at least 2 inches from the umbilicus), thigh (front), or upper arm. - **Rotation**: rotate sites and rotate injection spots within each site to reduce injection site reactions and lipohypertrophy. - **Pen**: single-dose pre-filled pen with auto-injector mechanism; click indicates full dose delivered. ### Storage - **Unopened pens**: store in refrigerator (36°F to 46°F / 2°C to 8°C) until expiration. - **After first use or removal from refrigeration**: may be stored at room temperature (up to 86°F / 30°C) for up to **21 days**. Discard after 21 days at room temperature even if medication remains. - **Do not freeze**: discard if frozen. - **Travel**: use an insulated medication travel case with ice pack for flights or trips > 2-3 hours in warm conditions. TSA allows medications in carry-on. ### Missed dose rules - **Missed dose within 4 days (96 hours)**: inject as soon as remembered, then resume normal weekly schedule. - **Missed dose beyond 4 days**: skip missed dose and resume normal weekly schedule on the next scheduled day. - **Never double-dose** to compensate. ### Disposal - Used pens are disposed of in an FDA-cleared sharps disposal container (not household trash). - Many pharmacies offer free sharps return programs. ## Special Populations ### Older adults (age ≥ 65) - No dose adjustment is required based on age alone. - Older adults may be more susceptible to gastrointestinal side effects leading to dehydration and acute kidney injury — monitor hydration and renal function. - Polypharmacy is more common; drug-interaction risk with insulin and sulfonylureas is clinically significant. ### Renal impairment - No dose adjustment required for mild, moderate, or severe renal impairment. - Monitor renal function in patients experiencing severe gastrointestinal side effects (vomiting, diarrhea, dehydration can precipitate acute kidney injury). - Use with caution in end-stage renal disease; clinical data are limited. ### Hepatic impairment - No dose adjustment required for mild, moderate, or severe hepatic impairment. - Limited experience in severe hepatic impairment — clinical judgment advised. ### Pregnancy and lactation - **Pregnancy**: not recommended. Animal studies showed fetal harm; no adequate human data. Discontinuation at least 2 months before planned conception is the conservative approach given the 5-day half-life (~25 days for ≥ 95% clearance). - **Lactation**: unknown whether tirzepatide is excreted in human milk. Risk-benefit discussion with the prescriber required. - **Contraception**: women using oral hormonal contraceptives require an additional non-oral contraceptive method for 4 weeks after initiation and for 4 weeks after each dose escalation due to delayed gastric emptying. ### Pediatric patients (< 18 years) - Not currently FDA-approved for pediatric use as of 2026. - Pediatric trials ongoing (see ClinicalTrials.gov for "tirzepatide pediatric"); pediatric approval may follow in 2026-2028, paralleling the pediatric semaglutide approval (Wegovy, 2022 for ≥ 12 years). ## Drug Interactions ### Oral medications (gastric emptying effect) Tirzepatide delays gastric emptying, potentially altering the absorption rate and extent of concurrently administered oral medications. Clinically significant considerations: - **Oral hormonal contraceptives**: reduced effectiveness during dose initiation and escalation. Use additional non-oral contraceptive method. - **Oral medications with narrow therapeutic index** (e.g., warfarin, levothyroxine, digoxin): monitor more closely during titration. Dose adjustments may be required. ### Insulin and sulfonylureas - **Hypoglycemia risk** increases substantially when tirzepatide is combined with insulin or insulin secretagogues (sulfonylureas such as glipizide, glyburide; meglitinides). - Dose reduction of insulin or sulfonylurea is typically required at tirzepatide initiation. - Monitor blood glucose closely during titration and after dose changes. ### Other GLP-1 receptor agonists - Concurrent use with other GLP-1 agonists (semaglutide, liraglutide, dulaglutide, exenatide) is **not recommended**. Additive mechanism without clinical benefit, increased side effect risk. ### Alcohol - No specific contraindication. May exacerbate gastrointestinal side effects and increase hypoglycemia risk when combined with insulin/sulfonylureas. History of pancreatitis warrants minimized alcohol consumption. ## Safety Profile and Side Effects Data from pivotal trials and FDA post-marketing surveillance. ### Most common adverse events (≥5% of patients) - Nausea (up to 33% at highest dose, usually transient during titration). - Diarrhea (up to 21%). - Vomiting (up to 13%). - Constipation (up to 11%). - Dyspepsia. - Abdominal pain. - Fatigue. - Injection site reactions (redness, itching). - Hair loss (thinning, typically reversible). ### Serious adverse events (rare but labeled) - Acute pancreatitis. - Acute kidney injury, typically secondary to severe dehydration from GI symptoms. - Severe hypoglycemia when combined with insulin or sulfonylureas. - Diabetic retinopathy complications (rapid glycemic improvement may exacerbate existing retinopathy). - Gallbladder disease (cholecystitis, cholelithiasis). - Thyroid C-cell tumors (boxed warning based on animal studies; human relevance uncertain; MTC/MEN 2 contraindication). ### Monitoring recommendations - Baseline and periodic HbA1c for T2D patients. - Weight, BMI, and blood pressure at each visit. - Lipid panel annually. - Monitor gastrointestinal tolerance, adjust titration pace. - Monitor for signs of pancreatitis, gallbladder disease, retinopathy changes. ## Tirzepatide vs Semaglutide: Head-to-Head Comparison As of 2026, tirzepatide and semaglutide are the two leading GLP-1-based therapies in the United States. Key differences: | Attribute | Tirzepatide | Semaglutide | |---|---|---| | Mechanism | Dual GIP + GLP-1 agonist | GLP-1 mono-agonist | | Brands (US) | Mounjaro, Zepbound | Ozempic (T2D), Wegovy (weight mgmt), Rybelsus (oral T2D) | | Typical max weight loss (trials) | Up to 20.9% (SURMOUNT-1) | Up to 14.9% (STEP 1) | | Typical HbA1c reduction (T2D) | –2.0 to –2.4% | –1.5 to –1.8% | | Route | Subcutaneous weekly | Subcutaneous weekly or oral daily | | FDA approval (weight) | Nov 2023 (Zepbound) | Jun 2021 (Wegovy) | | CV risk reduction approval | In development (SURPASS-CVOT) | March 2024 for Wegovy in CVD patients | | OSA approval | Dec 2024 (Zepbound) | Not approved | | Common GI side effects | Similar profile | Similar profile | Head-to-head SURMOUNT-5 trial (2024): tirzepatide 15 mg produced 20.2% average weight loss vs semaglutide 2.4 mg producing 13.7% over 72 weeks in adults with obesity without diabetes. ## Clinical Evidence: The SURMOUNT and SURPASS Programs ### SURPASS (tirzepatide for T2D) - **SURPASS-1** (2021, The Lancet): tirzepatide monotherapy in T2D. - **SURPASS-2** (2021, NEJM): vs semaglutide 1 mg in T2D. - **SURPASS-3** (2021, The Lancet): vs insulin degludec in T2D. - **SURPASS-4** (2022, The Lancet): vs insulin glargine in T2D with cardiovascular risk. - **SURPASS-CVOT** (ongoing, readout expected 2026–2027): cardiovascular outcomes trial. ### SURMOUNT (tirzepatide for obesity and related indications) - **SURMOUNT-1** (2022, NEJM): 72-week trial, up to 20.9% weight loss at 15 mg. - **SURMOUNT-2** (2023, The Lancet): in adults with T2D and obesity, up to 15.7% weight loss. - **SURMOUNT-3** (2023, Nature Medicine): intensive lifestyle intervention plus tirzepatide. - **SURMOUNT-4** (2024, JAMA): weight maintenance after initial tirzepatide treatment. - **SURMOUNT-5** (2024, NEJM): tirzepatide vs semaglutide head-to-head, favoring tirzepatide. - **SURMOUNT-OSA** (2024, NEJM): obstructive sleep apnea reduction in obese adults. - **SURMOUNT-MMO** (ongoing): cardiovascular outcomes specifically in obesity population. ## Tirzepatide Deep Dive: What Makes It Distinct Tirzepatide's clinical distinction stems from its **dual incretin receptor agonism**. GIP and GLP-1 both belong to the secretin family of gut hormones released postprandially; activating both simultaneously produces several amplified effects relative to single-agonist GLP-1 therapy: ### 1. Amplified insulin secretion GIP receptor activation augments the insulinotropic response of GLP-1 activation, producing greater postprandial insulin secretion in a glucose-dependent manner. This translates clinically into larger HbA1c reductions for T2D patients. ### 2. Differential effect on adipose tissue Preclinical and translational research suggests GIP receptor activation influences adipocyte function and energy expenditure. Whether GIP activation directly promotes lipolysis in humans remains under active investigation, but the clinical phenotype (greater weight loss than semaglutide at comparable doses) is consistent with additive effects beyond appetite suppression alone. ### 3. Tolerability of titration Clinical trials suggest that the dual mechanism may permit greater cumulative metabolic effect at doses with tolerable gastrointestinal profiles, although GI side effects remain the primary reason for treatment discontinuation in both tirzepatide and semaglutide users. ### 4. Durability of response SURMOUNT-4 demonstrated that continued tirzepatide use is essential for weight maintenance; discontinuation leads to substantial regain over 52 weeks. This reinforces the chronic-disease model of obesity pharmacotherapy: tirzepatide, like other incretin-based medications, is not a "cure" but a maintenance therapy requiring long-term adherence. ### 5. Emerging indications Beyond T2D and weight management, tirzepatide is under active investigation for: - Cardiovascular outcomes (SURPASS-CVOT, SURMOUNT-MMO). - Heart failure with preserved ejection fraction (HFpEF) — SUMMIT trial (published 2024, positive). - Nonalcoholic steatohepatitis (NASH). - Chronic kidney disease in T2D. - Pediatric populations (ongoing trials). Future FDA labeling expansions may further shift reimbursement dynamics and patient access. ## Frequently Asked Questions **What is tirzepatide used for?** In the United States, tirzepatide is FDA-approved under two brand names: **Mounjaro** for adults with type 2 diabetes (since May 2022) and **Zepbound** for chronic weight management (since November 2023) and for moderate-to-severe obstructive sleep apnea in adults with obesity (since December 2024). It is a once-weekly injectable dual GIP/GLP-1 receptor agonist. **How much does tirzepatide cost without insurance in 2026?** Typical cash price at retail pharmacies is approximately $1,000–$1,350 per month for brand Mounjaro or Zepbound. Eli Lilly's direct vial program (LillyDirect) offers lower pricing (~$349–$695 per month) for eligible self-pay patients on specific doses. Compounded tirzepatide pricing varies; availability is restricted in 2026 due to the FDA shortage being resolved. **Is tirzepatide covered by Medicare?** Coverage depends on indication. Mounjaro for type 2 diabetes is generally covered under Medicare Part D. Zepbound for weight management alone is statutorily excluded from Medicare coverage under the Social Security Act § 1860D-2(e)(2)(A). However, Zepbound for obstructive sleep apnea (FDA-approved December 2024) is increasingly covered by Part D plans as of 2026, and potential future FDA expansions (cardiovascular disease) could further expand coverage. **Does insurance cover tirzepatide for weight loss?** Private commercial insurance coverage of Zepbound for weight loss varies: approximately 30–50% of large employer plans offered some coverage in 2025, typically with step therapy requirements, BMI thresholds, and prior authorization. Coverage is expanding progressively as obesity is increasingly recognized as a chronic disease. **What is the difference between Mounjaro and Zepbound?** Both contain the same active ingredient — tirzepatide. Mounjaro is the FDA-approved brand for type 2 diabetes; Zepbound is the FDA-approved brand for chronic weight management and obstructive sleep apnea. The pens are nearly identical technically, but they are labeled and priced for their specific indications. Coverage rules differ significantly between the two brands. **Is compounded tirzepatide still available in 2026?** Availability is significantly restricted compared to the 2022–2024 shortage period. After the FDA removed tirzepatide from the Drug Shortage List in October 2024 and reconfirmed in December 2024, 503B outsourcing facilities had 60 days to cease compounding, and 503A pharmacies face state-by-state enforcement timelines. As of 2026, legally compounded tirzepatide is typically limited to patients with a documented clinical need for a compounded formulation materially different from the FDA-approved commercial product. Always verify the current FDA position at the [FDA Drug Shortage Database](https://www.accessdata.fda.gov/scripts/drugshortages/). **How much weight can I lose on tirzepatide?** In the SURMOUNT-1 clinical trial (New England Journal of Medicine, 2022), adults with obesity without diabetes lost on average 15.0% (5 mg dose), 19.5% (10 mg), and 20.9% (15 mg) of body weight over 72 weeks, versus 3.1% with placebo. Individual results vary substantially based on dose, duration, adherence, lifestyle, baseline weight, and individual biology. **How is tirzepatide different from semaglutide (Ozempic, Wegovy)?** Tirzepatide activates both GIP and GLP-1 receptors (dual mechanism); semaglutide activates only the GLP-1 receptor (mono-agonist). In the head-to-head SURMOUNT-5 trial (NEJM 2024), tirzepatide 15 mg produced 20.2% average weight loss vs semaglutide 2.4 mg producing 13.7% over 72 weeks. Tirzepatide generally achieves slightly greater HbA1c reduction in T2D as well. Side effect profiles are similar. **Who should not take tirzepatide?** People with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, known hypersensitivity to tirzepatide, active severe gastroparesis, or during pregnancy. A history of pancreatitis, gallbladder disease, or proliferative diabetic retinopathy requires careful risk-benefit assessment with a prescriber. **What are the side effects of tirzepatide?** The most common side effects are gastrointestinal: nausea (up to 33% at highest dose), diarrhea (up to 21%), vomiting (up to 13%), constipation, and abdominal pain. Most GI symptoms emerge during dose escalation and improve over time. Serious but rare adverse events include pancreatitis, acute kidney injury secondary to dehydration, severe hypoglycemia (with insulin/sulfonylureas), and gallbladder disease. **How quickly will I start losing weight on tirzepatide?** Most patients begin noticing weight loss within the first 4–8 weeks. Significant clinical weight loss typically emerges after 12–24 weeks, with continued loss over the first year and a plateau thereafter. Maintenance of weight loss requires continued therapy; discontinuation generally leads to partial or full regain. **Can I take tirzepatide if I have type 1 diabetes?** Tirzepatide is not approved for type 1 diabetes. It is FDA-approved only for type 2 diabetes. Off-label use in T1D is not recommended outside of research settings. **Can I stop tirzepatide once I reach my goal weight?** Evidence from SURMOUNT-4 and similar studies suggests that discontinuation leads to substantial weight regain over 12–18 months. Obesity is increasingly understood as a chronic disease requiring ongoing management. Any decision to taper or discontinue should be made in consultation with the prescriber. **How do I get a prescription for tirzepatide?** A valid prescription from a US-licensed healthcare provider is required. Pathways include primary care physicians, endocrinologists, obesity medicine specialists (ABOM-certified), cardiologists, or licensed telehealth providers. The prescriber evaluates medical history, laboratory results, and eligibility criteria. **Does tirzepatide interact with birth control pills?** Tirzepatide can reduce the effectiveness of oral hormonal contraceptives during dose initiation and escalation due to delayed gastric emptying. Patients using oral contraceptives are advised to use an additional non-oral contraceptive method for 4 weeks after starting tirzepatide and for 4 weeks after each dose escalation. Consult the full FDA label. **Is tirzepatide safe to take long-term?** Long-term safety data extend to approximately 2 years from pivotal trials, with ongoing outcomes studies (SURPASS-CVOT, SURMOUNT-MMO) assessing safety and efficacy over longer periods. No long-term safety concerns beyond those in the FDA label have been identified to date (2026). Continued monitoring is standard. **Can I inject tirzepatide at home?** Yes. Tirzepatide is administered via pre-filled single-dose pen (subcutaneous injection, once weekly). The injection is self-administered into the abdomen, thigh, or upper arm. Patient education on injection technique, rotation of sites, and storage (refrigerated before use, can be unrefrigerated for 21 days) is standard. **Does tirzepatide help with type 2 diabetes and weight loss together?** Yes. In adults with T2D and obesity, tirzepatide (as Mounjaro or Zepbound) produces both HbA1c reduction (typically –2.0 to –2.4%) and weight loss (typically 10–16% in the SURMOUNT-2 trial). This dual benefit is one reason tirzepatide has been rapidly adopted in diabetes care. **Is tirzepatide approved for cardiovascular disease?** As of 2026, tirzepatide is not yet FDA-approved for cardiovascular disease. The SURPASS-CVOT and SURMOUNT-MMO cardiovascular outcomes trials are ongoing with readouts expected 2026–2027. If results are positive, an FDA-approved cardiovascular indication could follow, similar to Wegovy's March 2024 CV approval. **Can I use tirzepatide for obstructive sleep apnea?** Yes. Zepbound (tirzepatide) received FDA approval in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. The indication is based on the SURMOUNT-OSA trial, which demonstrated significant reductions in apnea-hypopnea index. This approval has expanded insurance coverage for qualifying patients. **What is the difference between Mounjaro pens and Zepbound pens?** Mechanically, the two pen platforms are similar. The differences lie in the indication-specific labeling, patient education materials, insurance coverage rules, and pricing structures between the two brands — both produced by Eli Lilly. **Do I need to diet while taking tirzepatide?** The FDA label for Zepbound and tirzepatide's weight management indication specifies use "as an adjunct to a reduced-calorie diet and increased physical activity." Clinical trial results were obtained in the context of lifestyle counseling. Lifestyle change is not optional for optimal and durable results. **How long do the effects of tirzepatide last after discontinuation?** Tirzepatide's clinical effects diminish as the drug clears from the body (half-life ~5 days). Weight loss maintenance requires continued therapy; most patients regain a substantial portion of lost weight within 12–18 months after discontinuation, based on SURMOUNT-4 and similar studies. **Is tirzepatide available without a prescription?** No. Tirzepatide is a prescription-only medication in the United States. Purchasing tirzepatide from sources that do not require a prescription is illegal, unsafe, and often involves counterfeit or adulterated products. **Can I drink alcohol while taking tirzepatide?** No specific contraindication exists, but alcohol may exacerbate gastrointestinal side effects, increase the risk of hypoglycemia (particularly with insulin/sulfonylureas), and can complicate pancreatitis risk. Moderation is advised; patients with pancreatitis history should minimize alcohol consumption. **What happens if I miss a dose of tirzepatide?** If the missed dose is within 4 days of the scheduled injection, the patient should inject as soon as possible. If more than 4 days have passed, the patient should skip the missed dose and resume the normal weekly schedule. Consult the FDA label or your prescriber for dose-specific guidance. **Does tirzepatide affect pregnancy or fertility?** Tirzepatide is not recommended during pregnancy due to insufficient human data and evidence of developmental harm in animal studies. Contraception counseling is standard. Women using oral hormonal contraceptives require additional contraception during dose escalation due to gastric emptying effects. Discontinuation at least 2 months before planned conception is the conservative approach. **Can teenagers take tirzepatide?** Tirzepatide is currently FDA-approved only for adults (≥18 years). Pediatric trials are ongoing, and a pediatric indication may follow in the coming years, similar to semaglutide's pediatric obesity approval. **How do I find a tirzepatide provider near me in the United States?** Three main pathways in 2026: (1) in-person — primary care physician, endocrinologist, or ABOM-certified obesity medicine specialist (directory at [abom.org](https://www.abom.org/)); (2) hospital-based bariatric or weight management programs; (3) telehealth platforms with US-licensed clinicians operating across all 50 states. Telehealth is the fastest pathway (days to 1 week) while in-person specialist appointments can take 3-16 weeks depending on region. **Is tirzepatide available through telehealth in all 50 US states?** Yes. Tirzepatide is not a controlled substance, which simplifies telehealth prescribing. Licensed platforms operate in all 50 states through networks of US-licensed MDs, DOs, NPs, and PAs. State licensure compliance is required (the clinician must be licensed in the patient's state of residence). **What is the best alternative to tirzepatide if I cannot access or afford it?** Depends on goals and eligibility. For T2D: other GLP-1 agonists (semaglutide as Ozempic, dulaglutide as Trulicity) or non-GLP-1 diabetes medications. For weight loss without insurance access: phentermine (~$15-40/month, short-term), phentermine-topiramate (Qsymia, ~$200/month), naltrexone-bupropion (Contrave, ~$100-200/month after manufacturer programs). For BMI ≥ 35 with comorbidities: bariatric surgery (sleeve gastrectomy, gastric bypass) — typically covered by insurance. **How does tirzepatide compare to bariatric surgery?** Tirzepatide (up to 20-22% weight loss in trials) is approaching the efficacy of sleeve gastrectomy (60-70% excess weight loss ≈ 25-30% total body weight) over 1-2 years but is fully reversible on discontinuation. Bariatric surgery produces more durable long-term outcomes but is invasive, requires 6-12 months of insurance-mandated preparation, and carries surgical risks. Increasingly, combination approaches (surgery + GLP-1) are used in refractory cases. **What time of day should I inject tirzepatide?** Any time, with or without food. There is no pharmacologic reason to inject at a specific hour. Most patients select a convenient day and time (e.g., Sunday evening, Monday morning) and stick to it for consistency. Once-weekly dosing is the only requirement. **How should I store tirzepatide pens?** Unopened pens: refrigerate (36°F to 46°F / 2°C to 8°C). Once removed from refrigeration or after first use, store at room temperature (up to 86°F / 30°C) for up to 21 days. Do not freeze. For travel, use an insulated medication case with ice pack for flights or warm weather trips over 2-3 hours. **Can I inject tirzepatide while traveling by plane?** Yes. TSA permits injectable medications in carry-on luggage. Carry the pens in their original labeled packaging in an insulated case with a cold pack if flying longer than 2-3 hours. Declare the medication at security if asked. **Do I need to switch injection sites each week?** Rotating injection sites (abdomen, thigh, upper arm) and spots within each site is recommended to reduce injection site reactions and lipohypertrophy (fat thickening). Each site can be reused after a 2-3 week rotation. **Is tirzepatide safe for older adults over 65?** Yes, with monitoring. No dose adjustment based on age. Older adults may be more sensitive to gastrointestinal side effects leading to dehydration and acute kidney injury; more frequent follow-up is standard. Polypharmacy interactions with insulin and sulfonylureas are common and require monitoring. **Is tirzepatide safe for people with kidney disease?** Yes, with caution. No dose adjustment for mild, moderate, or severe renal impairment. However, severe gastrointestinal side effects (vomiting, diarrhea) can precipitate acute kidney injury through dehydration. Use with caution in end-stage renal disease; clinical data are limited in this population. **Can I take tirzepatide while also taking Ozempic or Wegovy?** No. Concurrent use of tirzepatide with another GLP-1 receptor agonist (semaglutide as Ozempic/Wegovy, liraglutide as Saxenda/Victoza, dulaglutide as Trulicity) is not recommended. The mechanisms overlap significantly without additive clinical benefit, and side effect risk increases. Transitioning from one to the other requires prescriber guidance. **Does tirzepatide affect my other prescription medications?** Yes, potentially. The delayed gastric emptying effect can alter absorption of some oral medications. Clinically relevant: oral hormonal contraceptives (reduced efficacy during titration), warfarin (monitor INR closer), levothyroxine (monitor TSH), digoxin (monitor levels). Insulin and sulfonylureas require dose reduction due to hypoglycemia risk. Always inform prescribers of all medications before starting tirzepatide. ## Glossary - **ABOM**: American Board of Obesity Medicine, the certification body for obesity medicine specialists in the United States. - **503A pharmacy**: a state-licensed pharmacy that compounds medications for individual patients pursuant to a valid prescription, under Section 503A of the Federal Food, Drug, and Cosmetic Act. - **503B outsourcing facility**: an FDA-registered facility that compounds medications in larger quantities under Section 503B of the Federal Food, Drug, and Cosmetic Act, subject to current Good Manufacturing Practice (cGMP) requirements. - **BMI (Body Mass Index)**: weight (kg) divided by height squared (m²). Used to classify underweight, normal, overweight, and obesity. - **Compounded medication**: a preparation made by a licensed pharmacist or outsourcing facility, not FDA-approved and not reviewed for safety, effectiveness, or quality by the FDA. - **Dual agonist**: a medication that simultaneously activates two distinct receptors. Tirzepatide is a dual GIP/GLP-1 receptor agonist. - **FDA**: U.S. Food and Drug Administration, the federal agency regulating drugs, biologics, and medical devices. - **GIP**: glucose-dependent insulinotropic polypeptide, a gut hormone released postprandially that stimulates insulin secretion. - **GLP-1**: glucagon-like peptide-1, a gut hormone that stimulates insulin secretion, suppresses glucagon, and slows gastric emptying. - **HbA1c**: glycated hemoglobin, a 3-month average measure of blood glucose control. - **Incretin**: gut hormone (GIP, GLP-1) that amplifies insulin secretion in response to oral glucose. - **Medicare Part D**: Medicare prescription drug coverage. - **Medicaid**: joint federal-state program providing health coverage to eligible low-income individuals. - **Mounjaro**: Eli Lilly brand name for tirzepatide approved for type 2 diabetes (2022). - **Ozempic / Wegovy / Rybelsus**: Novo Nordisk brand names for semaglutide (T2D, weight management, oral T2D respectively). - **Prior authorization (PA)**: insurance requirement that a prescriber document medical necessity before a medication is covered. - **Step therapy**: insurance requirement that a patient try and fail less-expensive alternatives before a specific medication is covered. - **SURMOUNT**: Eli Lilly's clinical trial program for tirzepatide in weight management and related indications. - **SURPASS**: Eli Lilly's clinical trial program for tirzepatide in type 2 diabetes. - **Titration**: gradual dose escalation to improve tolerability. - **Zepbound**: Eli Lilly brand name for tirzepatide approved for chronic weight management (2023) and obstructive sleep apnea (2024). ## Official Sources 2026 All data in this document are drawn from or cross-referenced against the following primary US sources: - [US Food and Drug Administration (FDA) — Drug Approvals and Databases](https://www.fda.gov/drugs/drug-approvals-and-databases) — FDA approval histories and label information. - [FDA Drug Shortage Database](https://www.accessdata.fda.gov/scripts/drugshortages/) — current shortage status for tirzepatide and semaglutide. - [FDA — Human Drug Compounding](https://www.fda.gov/drugs/human-drug-compounding) — regulatory framework for 503A and 503B compounding. - [Centers for Medicare & Medicaid Services (CMS)](https://www.cms.gov/) — Medicare and Medicaid coverage policy. - [Medicare.gov — Drug Coverage Search](https://www.medicare.gov/plan-compare/) — plan-specific formulary lookup. - [DailyMed (NIH / NLM)](https://dailymed.nlm.nih.gov/) — official FDA package inserts for Mounjaro and Zepbound. - [ClinicalTrials.gov](https://clinicaltrials.gov/) — registry of SURMOUNT and SURPASS trials. - [The New England Journal of Medicine](https://www.nejm.org/) — primary publication venue for SURMOUNT-1, SURMOUNT-OSA, and SURMOUNT-5. - [JAMA — The Journal of the American Medical Association](https://jamanetwork.com/) — publication venue for SURMOUNT-4. - [American Diabetes Association Standards of Care](https://diabetesjournals.org/care) — annually updated clinical guidelines. - [American Heart Association — Scientific Statements](https://www.heart.org/) — cardiovascular clinical guidelines. - [Obesity Medicine Association](https://obesitymedicine.org/) — clinical practice guidance in obesity medicine. - [American Board of Obesity Medicine (ABOM)](https://www.abom.org/) — certification directory for obesity medicine specialists. ## Additional Resources - [Eli Lilly Mounjaro patient site](https://www.mounjaro.com/) — official patient information and savings programs for type 2 diabetes. - [Eli Lilly Zepbound patient site](https://zepbound.lilly.com/) — official patient information, LillyDirect Self Pay, and savings programs. - [GoodRx — Tirzepatide pricing](https://www.goodrx.com/) — verified current retail pharmacy pricing. - [Medicare Plan Finder](https://www.medicare.gov/plan-compare/) — plan-by-plan drug coverage lookup. - [NIH MedlinePlus — Tirzepatide](https://medlineplus.gov/) — consumer-oriented drug information. ## About This Page tirzepatide-nearme.com is a free information and matching platform that connects eligible US-based patients with licensed telehealth providers, endocrinologists, and obesity medicine specialists across the United States. The platform does not manufacture, prescribe, dispense, or sell medications, does not provide medical advice, and is not a healthcare provider. Individual eligibility, treatment decisions, and outcomes are determined by licensed clinicians based on individual medical history and current evidence-based practice. **FDA Disclaimer**: Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Compounded preparations referenced in this document are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Tirzepatide is a prescription medication. Consult a licensed healthcare provider before initiating therapy. Individual results vary. Last updated: April 2026.